Used in targeted cancer therapies, particularly for tumors overexpressing FGFR2, such as certain gastric, breast, and endometrial cancers. Binds specifically to FGFR2 on cancer cells, blocking signaling pathways that drive tumor growth and survival. Enables precise delivery of cytotoxic agents when conjugated, enhancing treatment efficacy while minimizing damage to healthy tissues. Investigated in clinical trials for its role in immunotherapies, including bispecific antibodies engaging T cells to eliminate cancer cells. Also serves as a reference standard in antibody development and biosimilar testing.